Do you have (Nasdaq: SILO) on your radar yet?

StockWireNews

(Nasdaq: SILO) Keeps Heating Up On The Heels Of Breaking News (Multiple Technical Indicators Triggered)

May 21st

Greetings Readers,

Do you have (Nasdaq: SILO) on your radar yet?

If not... Why not?

Early this morning, the company dropped this massive news announcement: Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

With this news only just starting to make the rounds, SILO could be on the verge of drawing down a ton of breakout buzz.

It also doesn't hurt that SILO is displaying several technical indicators with bullish sentiment.

Right now Barchart is sharing that SILO has at least 10 technicals triggered across the short, medium, and long term.

Plus the website is even signaling its composite "Trend Seeker" indicator to be triggered!

SILO is also trading above 3 key technical lines of potential support in its 50-Day Simple Moving Average (SMA), its 200-Day SMA, and its 13-Day Exponential Moving Average.

Remember, this is a low float (under 3Mn shares) profile which means volatility can pop up at an instant, so it's important to watch this one closely.

Get (Nasdaq: SILO) on your screen before it's too late!

-----

On May 8th, we did something. Were you paying attention?

Just before bedtime, we alerted a Nasdaq low float profile to keep a close eye on. And if you did, a wild ride has since transpired.

From an open of $.079 on the 9th, that breakout idea ripped and roared all the way to a high of $.229 by May 16th.

That's an approximate run of 189% short term!

Then came May 15th and another Nasdaq idea alerted for its breakout potential.

Brought into focus around 9:00AM EST, that tech profile popped from around $4.08 to a high after the opening bell of $4.90.

That's another impressive tally of approximately 20%!

But now it's a new week and we're eyeing a ton of breakout potential.

In fact, one Nasdaq profile in particular is catching our eye for multiple reasons.

Firstly, it has a low float. And we mean, low.

Clocking in with fewer than 3Mn shares in its float according to Yahoo Finance, volatility will need to be carefully watched for throughout our coverage.

Secondly, bullish technical indicators are reigning supreme across the short, medium, and long term.

As of 12:00PM EST Monday, Barchart was reporting a total of 10 triggered!

Factor in occurrences of "Positive Results" early in 2024 for this past champ that ran approximately 30+% short term when it was profiled previously, and we may be looking at an explosive proposition early this week.

Drop what you're doing and pull up:

*Silo Pharma, Inc. (Nasdaq: SILO)*

Silo Pharma Inc. is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

Silo focuses on developing traditional therapies and psych-e-delic treatments in novel formulations and drug delivery systems.

And based on these potential catalysts, SILO could start to draw down a bunch of breakout buzz. Take a look:

No. 1 - Volatility Could Be Explosive Based On A Very Low Float Situation.

No. 2 - A Slew Of Bullish Technical Indicators May Suggest Something Cooking On The Horizon.

No. 3 - "Positive Results" Shows A PTSD Treatment Pushing Forward And Grabbing Headlines.

No. 4 - A Future $30Bn Alzheimer's Disease Market Up For Grabs While Silo Nears Key Acquisition.

No. 5 - 2024 Got Kicked Off With Positive Results In A Key Alzheimer's Study.

But more on those in a second...

Silo Pharma, Inc. - A Quick Overview

Silo is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.

They are focused on developing novel therapies that include conventional drugs and psych-e-delic formulations.

The Company’s lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders.

SP-26 is a time-release ket-a-mine-based loaded implant for fibromyalgia and chronic pain relief.

Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting the central nervous system with initial research indication in multiple sclerosis (MS).

Rare Disease Therapeutics

The company seeks to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psych-e-delic drugs, such as psi-lo-cybin, ket-a-mine, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders.

Silo's mission is to identify assets to license and fund the research which they believe will be transformative to the well-being of patients and the healthcare industry.

They have engaged in discussions with a number of world-renowned educational institutions and advisors regarding potential opp's and have formed a scientific advisory board that is intended to help advise management regarding potential acquisition and development of products.

In addition, Silo has entered into a license agreement with the University of Maryland, Baltimore, and is developing a Ket-a-mine polymer implant.

They have also recently entered into a sponsored research agreement with Columbia University pursuant to which we have been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ket-a-mine in combination with certain other compounds.

Silo plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this new line of business.

Silo's Progressing Pipeline

image

Grab More Key Company Details Here: Form 10-K. SILO's Website.

-----

As mentioned above, SILO has several potential breakout catalysts to start paying attention to now. Check them out:

No. 1 SILO Potential Catalyst - Volatility Could Be Explosive Based On A Very Low Float Situation.

According to info from Yahoo Finance's website, SILO has a fairly low float.

The website reports this profile to have roughly 2.54Mn shares in its float.

Why is that figure important? It's important on one crucial level. Volatility.

Could more positive company news in the first half of 2024 provide a near term spark?

-----

No. 2 SILO Potential Catalyst - A Slew Of Bullish Technical Indicators May Suggest Something Cooking On The Horizon.

Around 12:00PM EST Monday, Barchart was reporting several technical indicators to be triggered across the short, medium, and long term.

Here's a quick list:

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 100 Day MACD Oscillator
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

Make sure to watch these technical indicators closely moving forward.

-----

No. 3 SILO Potential Catalyst - "Positive Results" Shows A PTSD Treatment Pushing Forward And Grabbing Headlines.

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy

SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), ..., today announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). The PK study was conducted as part of non-GLP small animal dose-ranging study of SPC-15 completed in February 2024.

The activity of SPC-15 in the subjects or the PK study was evaluated over a 7-day repeat intranasal dose, including the processes of absorption, distribution, and excretion. Time to peak drug concentration (Tmax) occurred between 0.5 and 2 hours following intranasal administration compared to 2 hours following oral gavage administration. In previous findings from the non-GLP study, SPC-15 demonstrated rapid absorption with good exposure over a full 24-hour period, and based on these studies we determined an optimal once-per-day human intranasal dosing.

Silo CEO Eric Weisblum commented,Our evaluation of the PK profile for SPC-15 indicates effective and consistent exposure from intranasal administration of the drug. We believe these study results will be substantially replicated in humans.

Now completed, the non-GLP study will be followed by a progressive intellectual and neurological deterioration (PIND) study and then a GLP study, both slated to commence in 2024, and both of which are additional required steps before submission of an Investigational New Drug (IND) application for SPC-15 to the FDA.

Read the full article here.

-----

No. 4 SILO Potential Catalyst - A Future $30Bn Alzheimer's Disease Market Up For Grabs While Silo Nears Key Acquisition.

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

SPC-14 shows cognitive and stress reduction benefits in preclinical models

SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), ..., today announced that it has exercised its option to license Alzheimer’s disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.

Columbia University has discovered a therapeutic candidate that could bring relief and hope for Alzheimer’s patients and families,said Eric Weisblum, CEO of Silo.In our opinion, available treatments for AD remain largely inadequate. We believe that the cognitive improvement and stress reduction shown by SPC-14 in preclinical studies could hold promise for this underserved disease market.

The global Alzheimer’s disease therapeutics market size is forecasted to exceed $30.8Bn by 2033, with a CAGR of 18.8% from 2024 to 20331. Rising prevalence of the disease in the expanding elderly population and advancements in neurological research are expected to drive market growth.

Silo believes that SPC-14 should be eligible for development under the FDA’s 505(b)(2) regulatory pathway.

Read the full article here.

-----

No. 5 SILO Potential Catalyst - 2024 Got Kicked Off With Positive Results In A Key Alzheimer's Study.

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety.

SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), ..., today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals.

Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic.

We believe that today's announcement, along with our past studies of SPC-14 conducted in female rodents, lends credibility to our discovery of a therapeutic that could bring relief to patients and families suffering from Alzheimer’s disease, a debilitating disease that degrades cognitive function and can erase a lifetime of memories. We look forward to updating our shareholders on the next steps and data needed to advance SPC-14 to a clinical study,stated Eric Weisblum, Chief Executive Officer of Silo Pharma.

Read the full article here.

-----

(Nasdaq: SILO) Recap - Pay Attention To These Explosive Potential Catalysts

No. 1 - Volatility Could Be Explosive Based On A Very Low Float Situation.

No. 2 - A Slew Of Bullish Technical Indicators May Suggest Something Cooking On The Horizon.

No. 3 - "Positive Results" Shows A PTSD Treatment Pushing Forward And Grabbing Headlines.

No. 4 - A Future $30Bn Alzheimer's Disease Market Up For Grabs While Silo Nears Key Acquisition.

No. 5 - 2024 Got Kicked Off With Positive Results In A Key Alzheimer's Study.

-----

Coverage is officially initiated on Silo Pharma, Inc. (Nasdaq: SILO). Get this breakout idea on your radar quickly.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc-laim-er here: www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 10/12/22 and ending on 10/13/22 to publicly disseminate information about (SILO) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (SILO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 8/1/23 and ending on 8/2/23 to publicly disseminate information about (SILO) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (SILO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 5/20/24 and ending on 5/21/24 to publicly disseminate information about (SILO) via Website, Email and SMS. SWN Media LLC was paid eighteen thousand USD via bank wire transfer. We own zero shares of (SILO). To date we have been compensated a total of sixty thousand five hundred USD via bank wire transfer to disseminate information about (SILO). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Axiom Financial, Inc., TD Media LLC has been hired for a period beginning on 05/20/2024 and ending on 05/21/2024 to publicly disseminate information about (SILO:US) via digital communications. We have been paid an additional eighteen thousand dollars USD. We expect to be paid an additional eighty-two thousand dollars USD to run a longer term branding and awareness campaign. When the additional compensation comes in, this disclosure will be updated. To date we have been paid one hundred twenty thousand five hundred dollars USD to disseminate information about (SILO:US) via digital communications. We own zero shares of (SILO:US). lifewatermedia.com/silo-disclosure-354/